Ipca Laboratories Limited (BOM:524494)
India · Delayed Price · Currency is INR 1,598.30
+14.20 (0.90%)
At close: Jun 22, 2026
Ipca Laboratories Stock Forecast
Stock Price Forecast
According to 18 analysts polled by S&P Global, Ipca Laboratories stock has a consensus rating of "Buy" and an average price target of ₹1,720. The average 1-year stock price forecast is 7.59% higher than the current stock price, while the lowest is ₹1,405 (-12.09%) and the highest is ₹1,887 (+18.06%).
Price Target: ₹1,720 (+7.59%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ipca Laboratories stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 9 | 9 | 10 |
| Buy | 6 | 5 | 5 | 5 | 5 | 5 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 17 | 17 | 17 | 17 | 16 | 17 |
Financial Forecast
Revenue This Year
107.71B
from 96.46B
Increased by 11.66%
Revenue Next Year
120.16B
from 107.71B
Increased by 11.55%
EPS This Year
55.25
from 46.94
Increased by 17.70%
EPS Next Year
65.73
from 55.25
Increased by 18.97%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 109.1B | ||
| Avg | 107.7B | ||
| Low | 105.8B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 13.1% | ||
| Avg | 11.7% | ||
| Low | 9.7% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 58.50 | ||
| Avg | 55.25 | ||
| Low | 49.50 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 24.6% | ||
| Avg | 17.7% | ||
| Low | 5.5% |